Antiviral Drug News and Research

RSS

Discovery allows study of naturally occurring forms of HCV in the lab

Worldwide, 185 million people have chronic hepatitis C. Since the late 1980s, when scientists discovered the virus that causes the infection, they have struggled to find ways to grow it in human cells in the lab -- an essential part of learning how the virus works and developing new effective treatments.

19 Aug 2015

Researchers develop new genomic data set on Lassa virus

An international team of researchers has developed the largest genomic data set in the world on Lassa virus (LASV).

14 Aug 2015

First patient enrolled in Contravir‘s FV-100 Phase 3 study to prevent shingles, shingles-associated pain

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the first patient has been enrolled in the Company's pivotal Phase 3 clinical study, study 007, of FV-100 to prevent the debilitating shingles-associated pain known as post-herpetic neuralgia (PHN).

3 Aug 2015

Ledipasvir/sofosbuvir combination approved for hepatitis C treatment does not require antiviral drug

The drug approved to treat patients infected with the hepatitis C virus needs no help from other antivirals, according to a study released online this week in the journal Hepatology.

2 Jul 2015

Baruch S. Blumberg Institute engaged to conduct study using ContraVir's new HBV therapeutic candidate

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has engaged the Baruch S. Blumberg Institute, the non-profit research sister organization of the Hepatitis B Foundation, to conduct a series of experiments using ContraVir's hepatitis B program, CMX157.

3 Jun 2015

Research finding could explain why HIV envelope protein has a long tail

Virologists at Emory University School of Medicine, Yerkes National Primate Research Center, and Children's Healthcare of Atlanta have uncovered a critical detail explaining how HIV assembles its infectious yet stealthy clothing.

3 Jun 2015

Telbivudine drug prevents perinatal transmission of HBV

The antiviral drug telbivudine prevents perinatal transmission of hepatitis B virus (HBV), according to a study in the June issue of Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

2 Jun 2015

Researchers show potential of stem cell-based therapy in treating brain-metastatic breast cancer

Investigators from Massachusetts General Hospital and the Harvard Stem Cell Institute have developed an imageable mouse model of brain-metastatic breast cancer and shown the potential of a stem-cell-based therapy to eliminate metastatic cells from the brain and prolong survival.

27 Apr 2015

Personalized gene therapy to fight against cancer

The fight to treat cancer and eradicate tumors will likely benefit from a new set of treatments if early development phases continue to show promise, according to Kalorama Information. The healthcare market research publisher stated that gene therapies that are able to deliver genetic material to a specific cell population or tumor that will result in the destruction of the tumor.

25 Mar 2015

Clinical study launched to evaluate effectiveness of new HCV therapy in Washington, D.C.

Officials from the National Institutes of Health and the city of Washington, D.C., launched a clinical trial to examine whether primary care physicians and other health care providers, such as nurse practitioners and physician assistants, can use a new antiviral therapy as effectively as specialist physicians to treat people with hepatitis C virus (HCV) infection.

9 Mar 2015

Research shows effectiveness of Tamiflu

Earlier this month, the Centers for Disease Control and Prevention recommended the use of antiviral drugs to help treat influenza, in a year when the available vaccine is not a good match for the current strain.

30 Jan 2015

MedExpress physicians offer appropriate option to assess, treat flu or cold symptoms

As flu season progresses, patients across the country continue to seek care for flu and illness symptoms at a variety of health care locations. From doctors' offices to emergency rooms, many patients find it difficult to determine the best option based on their symptoms. MedExpress physicians remind patients, that in many cases, urgent care centers offer a convenient, appropriate option for the assessment and treatment of non-severe flu or cold symptoms.

21 Jan 2015

Early estimates indicate flu vaccine is providing little protection in US

Each year the Centers for Disease Control and Prevention (CDC) undertake flu vaccine effectiveness studies. Early estimates for the current season indicate that those people (all ages) who had the flu vaccine were only 23% less likely to have to go to the doctor because of flu (influenza).

16 Jan 2015

NIAID awards contracts to support early-stage human clinical trials of infectious disease treatments

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded contracts to three organizations to support early-stage human clinical trials of investigational infectious disease treatments. The new awards for the Phase I Clinical Trial Units for Therapeutics increases the number of funded organizations under the program from two to three, expanding capacity for conducting early safety testing of novel investigational drugs.

15 Jan 2015

ContraVir granted Type B meeting with FDA to discuss proposal for FV-100 Phase 3 trial

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has been granted a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss its proposal for the design of a Phase 3 trial of ContraVir's lead antiviral candidate, FV-100.

7 Jan 2015

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, and ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the companies have entered into a strategic collaboration for the further clinical development and commercialization of CMX157.

18 Dec 2014

Antiviral Drug News and Research

Discovery allows study of naturally occurring forms of HCV in the lab

Researchers develop new genomic data set on Lassa virus

First patient enrolled in Contravir‘s FV-100 Phase 3 study to prevent shingles, shingles-associated pain

Ledipasvir/sofosbuvir combination approved for hepatitis C treatment does not require antiviral drug

Baruch S. Blumberg Institute engaged to conduct study using ContraVir's new HBV therapeutic candidate

Research finding could explain why HIV envelope protein has a long tail

Telbivudine drug prevents perinatal transmission of HBV

Researchers show potential of stem cell-based therapy in treating brain-metastatic breast cancer

Personalized gene therapy to fight against cancer

Clinical study launched to evaluate effectiveness of new HCV therapy in Washington, D.C.

Research shows effectiveness of Tamiflu

MedExpress physicians offer appropriate option to assess, treat flu or cold symptoms

Early estimates indicate flu vaccine is providing little protection in US

NIAID awards contracts to support early-stage human clinical trials of infectious disease treatments

ContraVir granted Type B meeting with FDA to discuss proposal for FV-100 Phase 3 trial

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Monash University, 60P Australia partner to develop Fenretinide drug for dengue fever

UTMB researchers receive awards at American Society of Tropical Medicine and Hygiene meeting

Experimental Ebola treatments to be trialled in West Africa next month

UF Health researcher finds way to grow human norovirus

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News